Pharmaceutical compositions comprising cyclic carbonate nucleoside analogs and uses thereof

By adding fillers, disintegrants and lubricants to the cyclic carbonate nucleoside analog pharmaceutical composition, the fluidity and stability problems in their preparation and storage are solved, forming high dissolution and long-term stable oral solids Preparation, used to treat viral infections such as novel coronavirus and cat infectious peritonitis.

CN119033800APending Publication Date: 2024-11-29GUANGDONG CHENKANG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411069188.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing cyclic carbonate nucleoside analog pharmaceutical compositions have defects such as poor powder flowability, poor water solubility and unstable physical and chemical properties in preparation and storage, which affects its application as a pharmaceutical preparation.

Method used

By adding fillers, disintegrants and lubricants, a pharmaceutical composition containing cyclic carbonate nucleoside analogs is prepared, and its molding and stability is optimized to form a high dissolution and high bioavailability oral solid preparation with high dissolution and high bioavailability .

Benefits of technology

It has achieved high dissolution, good compatibility, content uniformity and long-term stability of the pharmaceutical composition, and is suitable for commercial production, which has significantly improved its therapeutic effect in the treatment of viral infections such as novel coronavirus and cat infectious peritonitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The invention provides a pharmaceutical composition containing a cyclic carbonate nucleoside analogue, the pharmaceutical composition comprises pharmaceutically acceptable salts of a compound represented by a formula I and auxiliary materials, and the auxiliary materials comprise a filler, a disintegrating agent and a lubricant, the filling agent is selected from one or more of lactose, microcrystalline cellulose, starch hydrolyzed oligosaccharide, sorbitol, mannitol and silicified microcrystalline cellulose. An oral solid preparation prepared from the pharmaceutical composition disclosed by the invention has good compatibility, extremely high dissolution rate, good content uniformity and excellent pharmacokinetic properties.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a pharmaceutical composition comprising a cyclic carbonate nucleoside analog and application thereof. Background Art

[0002] Coronavirus is a type of virus that is widely found in nature. It is named because the virus looks like a crown when observed under an electron microscope. So far, it has been found that coronavirus only infects vertebrates and can cause respiratory, digestive and nervous system diseases in humans and animals. Respiratory syncytial virus (RSV) can cause lower respiratory tract infections such as bronchiolitis and pneumonia in infants, and upper respiratory tract infections such as rhinitis and colds in children and adults. There is currently no effective chemical drug to treat it.

[0003] Feline infectious peritonitis (FIP) is a viral disease caused by a feline coronavirus mutation carried in cats. It is divided into wet FIP ​​and dry FIP. The general symptoms of wet FIP ​​are repeated fever, obvious abdominal swelling, long-term hen squat, listlessness, diarrhea, yellow stool, decreased appetite, and messy hair. Dry FIP is often not accompanied by ascites. The lesions mainly invade tissues and organs such as the eyes, central nervous system, kidneys, and liver, and form granulomas in these parts. Cats have symptoms such as convulsions, epilepsy, diarrhea, iris lesions, hind drive weakness, eye inflammation, and jaundice. Cats infected with FIPV are difficult to diagnose in the early stage, and the disease progresses rapidly. They enter the late stage within a few months. In the absence of specific drugs, cats almost all die. However, there is no effective drug on the market that can be used to treat feline infectious peritonitis.

[0004] Porcine epidemic diarrhea (PED) is a highly contagious enteric disease of pigs caused by porcine epidemic diarrhea virus (PEDV). PED virus belongs to the genus Coronavirus of the family Coronaviridae. Currently, there is no specific treatment for PED. Feline calicivirus (FCV) is currently considered to be closely related to feline stomatitis. Inhibiting feline calicivirus can effectively alleviate or cure feline stomatitis.

[0005] It is known that the marketed drug remdesivir (RDV) has a significant effect on the treatment of coronavirus. It can undergo intracellular phosphorylation under the stimulation of biological cell kinases, and generate nucleoside triphosphates (NTPs) after action, which can inhibit the biological activity of RNA polymerase and ultimately inhibit the replication and transcription of viral RNA, thereby achieving the treatment and / or prevention of diseases caused by coronavirus infection. However, remdesivir has poor oral bioavailability and can only be administered by injection at present.

[0006] After modifying the parent nucleoside of RDV (GS-441524), the researchers prepared compounds of formula I and their pharmaceutically acceptable salts, which have higher drugability against SARS-CoV-2 and FIPV, as well as lower cytotoxicity and higher oral bioavailability.

[0007] Chinese invention patent CN 114437159 A discloses a compound of formula Ⅰ:

[0008] Formula I

[0009] However, the compound of formula I still has some defects, such as being difficult to prepare into a solid with good powder fluidity (usually in a foamy state), having extremely poor water solubility, unstable physical and chemical properties, and being easily degraded, which are not conducive to the preparation and storage of raw materials and preparations.

[0010] Therefore, Chinese invention patent 202311210395.3 further prepares the compound of formula I into salts, such as the compound of formula II and the compound of formula III, and the above defects can be effectively improved. At the same time, the results of the pharmacokinetic evaluation in rats showed that the relative oral bioavailability of the compound of formula II relative to GS-441524 was 338.6%, which was also significantly higher than that of the compound of formula I.

[0011] The present invention aims to provide a pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of formula I for use in treating diseases caused by viruses. Summary of the invention

[0012] The present invention provides a pharmaceutical composition comprising a cyclic carbonate nucleoside analog and an application thereof, so as to solve the defect that the compound of formula I in the prior art is not conducive to the preparation and storage of raw materials and preparations, so as to achieve that the oral solid preparation prepared by using the pharmaceutical composition has high solubility, high bioavailability and long-term stability, thereby effectively treating diseases caused by the new coronavirus (SARS-CoV-2), feline infectious peritonitis virus (FIPV), respiratory syncytial virus (RSV), porcine epidemic diarrhea virus (PEDV) and / or feline calicivirus (FCV) and the like.

[0013] In a first aspect, the present invention provides a pharmaceutical composition comprising a cyclic carbonate nucleoside analog, comprising a pharmaceutically acceptable salt of a compound of formula I and an excipient,

[0014] Formula I

[0015] The auxiliary materials include fillers, disintegrants and lubricants, wherein the fillers are selected from one or more of lactose, microcrystalline cellulose, starch hydrolyzed oligosaccharides, sorbitol, mannitol and silicified microcrystalline cellulose. Among them, microcrystalline cellulose is preferably microcrystalline cellulose 112.

[0016] In some preferred embodiments of the present invention, the filler is selected from lactose and / or microcrystalline cellulose.

[0017] In some other preferred embodiments of the present invention, the filler is selected from microcrystalline cellulose and / or mannitol. Further preferably, the filler is selected from microcrystalline cellulose and mannitol, and the mass ratio of the two is preferably about 2:1.

[0018] According to the pharmaceutical composition comprising cyclic carbonate nucleoside analogs provided by the present invention, the pharmaceutically acceptable salt of the compound of formula I is the hydrobromide salt of the compound of formula II and / or the hydrochloride salt of the compound of formula III; Formula II Formula III.

[0019] According to the pharmaceutical composition containing cyclic carbonate nucleoside analogs provided by the present invention, the disintegrant is selected from one or more of modified starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose or cross-linked polyvinylpyrrolidone.

[0020] Preferably, the disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, and modified starch.

[0021] According to the pharmaceutical composition containing cyclic carbonate nucleoside analogs provided by the present invention, the lubricant is selected from one or more of talc, silicon dioxide, calcium stearate, magnesium stearate, sodium stearyl fumarate or stearic acid.

[0022] Preferably, the lubricant is selected from one or more of talc, silicon dioxide, magnesium stearate and sodium stearyl fumarate.

[0023] More preferably, the lubricant is selected from silicon dioxide and / or magnesium stearate.

[0024] According to the pharmaceutical composition containing cyclic carbonate nucleoside analogs provided by the present invention, the pharmaceutical composition comprises, by weight percentage: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of a filler, 2-10% of a disintegrant and 0.5-8% of a lubricant.

[0025] Preferably, in terms of weight percentage, the pharmaceutical composition comprises: 10-30% of a pharmaceutically acceptable salt of the compound of formula I, 55-80% of a filler, 3-8% of a disintegrant and 1-8% of a lubricant.

[0026] More preferably, the pharmaceutical composition comprises, by weight percentage: 10-15% of a pharmaceutically acceptable salt of the compound of formula I, 70-80% of a filler, 4-8% of a disintegrant and 2-8% of a lubricant.

[0027] In some embodiments of the present invention, the pharmaceutical composition comprises, by weight percentage: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of silicified microcrystalline cellulose, 2-10% of cross-linked polyvinylpyrrolidone and 0.5-8% of magnesium stearate.

[0028] In some embodiments of the present invention, the pharmaceutical composition comprises, by weight percentage: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of silicified microcrystalline cellulose, 2-10% in total of pregelatinized starch and cross-linked sodium carboxymethyl cellulose, and 0.5-8% in total of silicon dioxide and magnesium stearate.

[0029] In some embodiments of the present invention, the pharmaceutical composition comprises, by weight percentage: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of mannitol and starch hydrolyzed oligosaccharides, 2-10% of cross-linked polyvinylpyrrolidone and sodium carboxymethyl starch, and 0.5-8% of magnesium stearate.

[0030] In some embodiments of the present invention, the pharmaceutical composition comprises, by weight percentage: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of microcrystalline cellulose and lactose, 2-10% of cross-linked sodium carboxymethyl cellulose, and 0.5-8% of silicon dioxide and magnesium stearate.

[0031] In some embodiments of the present invention, the pharmaceutical composition comprises, by weight percentage: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of microcrystalline cellulose and lactose, 2-10% of cross-linked sodium carboxymethyl cellulose and pregelatinized starch, and 0.5-8% of talc and magnesium stearate.

[0032] In some embodiments of the present invention, the pharmaceutical composition comprises, by weight percentage: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of microcrystalline cellulose and mannitol, 2-10% of cross-linked sodium carboxymethyl cellulose and pregelatinized starch, and 0.5-8% of talc and magnesium stearate.

[0033] In some embodiments of the present invention, the pharmaceutical composition comprises, by weight percentage: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of microcrystalline cellulose and mannitol, 2-10% of cross-linked sodium carboxymethyl cellulose, and 0.5-8% of silicon dioxide and magnesium stearate.

[0034] In a second aspect, the present invention provides a pharmaceutical preparation comprising the above-mentioned pharmaceutical composition comprising a cyclic carbonate nucleoside analog.

[0035] Preferably, the pharmaceutical preparation is an oral solid preparation, preferably, the oral solid preparation is a tablet or a capsule, more preferably a tablet.

[0036] In a third aspect, the present invention provides a method for preparing the above-mentioned pharmaceutical preparation, comprising: uniformly mixing a prescribed amount of a pharmaceutically acceptable salt of a compound of formula I, a filler, a disintegrant and a lubricant, pressing the mixture into tablets by a tablet press or filling the mixture into capsules by a capsule filling machine, adding a desiccant for packaging, and sealing the mixture for storage.

[0037] In some specific embodiments of the present invention, the preparation method comprises the following steps: The pharmaceutically acceptable salt of the compound of formula I, the filler, the disintegrant and the lubricant in the prescribed amount are sieved and dispersed separately for use, and the sieve is selected from 20 mesh to 80 mesh, preferably 40 mesh; Then add the dispersed materials into the mixer and mix them evenly; then use the tablet press to press them into tablets or use the capsule filling machine to fill them into capsules; Finally, put the tablets or capsules into a high-density polyethylene bottle, add desiccant, and seal it for storage.

[0038] In a fourth aspect, the present invention provides use of the above-mentioned pharmaceutical composition comprising a cyclic carbonate nucleoside analog or the above-mentioned pharmaceutical preparation in the preparation of a drug for treating and / or preventing diseases caused by viral infection.

[0039] The viruses include coronavirus, influenza virus, respiratory syncytial virus, Flaviviridae virus, Filoviridae virus, feline coronavirus and feline calicivirus, etc. Preferably, the virus is the new coronavirus SARS-CoV-2, feline infectious peritonitis virus FIPV, respiratory syncytial virus RSV, porcine epidemic diarrhea virus PEDV and / or feline calicivirus FCV.

[0040] The present invention provides a pharmaceutical composition containing a cyclic carbonate nucleoside analog and its application. By investigating the compatibility of raw and auxiliary materials and screening the dosage of auxiliary materials, the compatibility, mixing uniformity, content uniformity and slow dissolution of oral solid preparations are solved, so that the oral solid preparation has good compatibility, extremely high dissolution, good content uniformity and excellent pharmacokinetic properties. With pH=1.0 hydrochloric acid solution (simulated gastric fluid) as the dissolution medium, the dissolution rate of the in vitro dissolution test for 15 minutes is above 85%.

[0041] Furthermore, the present invention solves the stability problem of the preparation by selecting the combination of auxiliary materials, dosage, model and product packaging, so that the oral solid preparation has excellent quality and long-term stability. The preparation method of the oral solid preparation of the present invention is simple, low-cost and suitable for commercial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 This is a comparison chart of the dissolution curves of tablets produced by prescriptions 7 to 10 in aqueous media.

[0043] Figure 2 This is a comparison chart of the dissolution curves of tablets produced by Prescription 11, Prescription 9, and Prescription 12 in aqueous media. DETAILED DESCRIPTION

[0044] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0045] Unless otherwise specified, all words (including technical terms and scientific terms) used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. Experimental methods without specific conditions in the following examples are usually based on conventional experimental conditions.

[0046] The detection methods for evaluation indicators such as content, related substances, dissolution, and dissolution curve of the pharmaceutical preparations in the following examples are as follows: The content of the compound of formula II is consistent with the relevant substance testing method.

[0047] Related substance testing methods: Determined by high performance liquid chromatography (Appendix 0512).

[0048] Test solution: Take an appropriate amount of fine powder of the product, weigh it accurately, add diluent (acetonitrile) to dissolve it, ultrasonicate for about 10 minutes, make up to volume with acetonitrile to contain about 0.25 mg of compound of formula II per 1 ml, and take the filtrate as the test solution.

[0049] Related substance reference solution: Accurately measure 1 ml of the test sample solution and place it in a 100 ml volumetric flask, then make up to volume with acetonitrile as the reference solution.

[0050] System suitability solution: Accurately weigh an appropriate amount of the reference compound of Formula II, place it in a 100 ml volumetric flask, add 2.0 ml of 0.1 mol / L HCl solution, let it stand for 30 minutes, add acetonitrile to dissolve and dilute to the scale, shake well, and use it as the system suitability solution.

[0051] Chromatographic conditions and system suitability: Octadecylsilane bonded silica gel was used as filler; water was used as mobile phase A; acetonitrile was used as mobile phase B, and gradient elution was performed according to Table 1 below; the column temperature was 30°C, and the detection wavelength was 243nm.

[0052] Table 1

[0053] Determination of related substances: Accurately measure 10μl of the system suitability solution, test solution, and reference solution filtrate, inject into the liquid chromatograph, record the chromatogram, the impurity peak separation should be greater than 2, calculated according to the corrected peak area.

[0054] Content test method: The test sample preparation method, chromatographic conditions and system suitability are consistent with those under related substances.

[0055] Content reference solution: Accurately weigh an appropriate amount of the reference compound of formula II, add diluent (acetonitrile) to dissolve, and dilute with acetonitrile to a concentration of about 0.25 mg / ml as the reference solution.

[0056] Content determination method: Accurately measure 10 μl of the test solution and the reference solution filtrate, inject into the liquid chromatograph, record the chromatogram, and calculate the peak area according to the external standard method.

[0057] Dissolution test method: Test sample: Take this product and follow the dissolution and release test method (Appendix 0931 Method 2 of the 2020 edition of the Chinese Veterinary Pharmacopoeia), using 900 ml of hydrochloric acid solution (pH = 1) as the dissolution medium, and the speed is 75 revolutions per minute. Operate according to the law, after 15 minutes, take 10 ml of the solution and filter it, accurately measure an appropriate amount of the filtrate, dilute it with acetonitrile to make a solution containing about 5.6 μg of Formula II compound per 1 ml, shake well, and use it as the test solution.

[0058] Take an appropriate amount of the reference substance of the compound of formula II, weigh it accurately, and add hydrochloric acid solution (pH = 1)-acetonitrile (20:80) to quantitatively dilute it to make a solution containing about 5.6 μg of the reference substance of the compound of formula II per 1 ml, which is used as the reference substance solution.

[0059] Determine according to high performance liquid chromatography (Appendix 0512), use octadecylsilane bonded silica gel as filler; use 0.1% phosphoric acid aqueous solution (adjust pH to 6.0±0.1 with triethylamine) as mobile phase A, acetonitrile as mobile phase B, column temperature at 40°C, detection wavelength at 243nm, and perform gradient elution according to Table 2. Accurately measure 10μl of the test solution and reference solution and inject them into the liquid chromatograph, record the chromatogram, and calculate the dissolution amount of each sample according to the external standard method. It should comply with the regulations.

[0060] Table 2

[0061] Dissolution curve: According to the dissolution and release determination method (Appendix 0931 Method 2), the test method is consistent with the dissolution method. The difference is that water is used as the dissolution medium, and samples are taken for testing after 5, 10, 15, 20, 30, and 45 minutes.

[0062] Unless otherwise specified in the following examples, all raw materials and reagents are commercially available or prepared by conventional methods in the art. The compound of formula II is self-made by the company (see Example 6 in Chinese invention patent application 202311210395.3: Preparation of hydrobromic acid (crystalline form A) salt of compound II); silicified microcrystalline cellulose, microcrystalline cellulose (brand: PH112, PH102), starch hydrolyzed oligosaccharides, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, and sodium stearyl fumarate were purchased from J. Rettenmaier & Soehne GmbH + Co KG, Germany; lactose was purchased from Metzenhagen GmbH & Co. KG, Germany; pregelatinized starch (brand: Starch 1500) was purchased from Shanghai Colorcon Coating Technology Co., Ltd.; mannitol was purchased from SPI Pharma; cross-linked polyvinylpyrrolidone was purchased from Chongqing Steckreidenmaier Materials Technology Co., Ltd.; magnesium stearate was purchased from Huzhou Zhanwang Pharmaceutical Co., Ltd.; silicon dioxide was purchased from Evonik Specialty Chemicals (Shanghai) Co., Ltd.; talc was purchased from Sibaiquan Chemicals (Shanghai) Co., Ltd.; desiccant was purchased from Shanghai Yingqi Desiccant Co., Ltd.; high-density polyethylene bottles were purchased from Hebei Jixing Pharmaceutical Packaging Co., Ltd.

[0063] Example 1

[0064] Compatibility test of compound II with auxiliary materials

[0065] The compatibility evaluation index is the total impurities of the relevant substances.

[0066] The present invention studies the compatibility of the compound of formula II with various excipients in accordance with the "Basic Technical Guiding Principles for the Study of Chemical Drug Preparations", that is, conducts an influencing factor test, wherein the compound of formula II and various excipients are uniformly mixed in an appropriate proportion, placed in a weighing bottle, and placed open at high temperature of 60°C and high humidity of 90%RH, and samples are taken for inspection at 0 day, 5 days, and 10 days respectively; and the compatibility of the compound of formula II with various excipients is studied under light (total illumination of not less than 1.2×10 6 Lux·hr, near ultraviolet energy not less than 200w·hr / m 2 ) conditions, samples were taken for testing at 0 days and 12 days respectively; the compatibility of different excipients with the compound of formula II was compared using total impurities as an indicator. The results are shown in Table 3.

[0067] Table 3 Total impurity test results of compatibility test samples

[0068] As shown in Table 3, the degradation of the compound of formula II mainly occurs under high humidity conditions, and high temperature conditions have a slight effect. Analysis shows that the main reason for its degradation is the influence of moisture in the environment, followed by the influence of the water content of the material itself, and finally the influence of high temperature. Sucrose, calcium hydrogen phosphate, cross-linked polyvinylpyrrolidone, pregelatinized starch and the compound of formula II have poor compatibility, so caution should be exercised when using them, and the selection of auxiliary material models and dosages should be fully examined. The present invention first excludes sucrose and calcium hydrogen phosphate. These two auxiliary materials are used as fillers in large amounts and have a greater risk of unqualified stability; the other two disintegrants, cross-linked polyvinylpyrrolidone and pregelatinized starch, are used in small amounts, and further experiments will be conducted to determine whether to adopt them.

[0069] Example 2

[0070] Add excipients to the compound of formula II to make tablets and select suitable excipients. The tablet preparation method is as follows: (1) Pass the API and excipients through a 40-mesh sieve respectively and set aside; (2) Take the prescribed amount of API and excipients, add them into the mixer, and mix them evenly; (3) Determine the content and moisture content of the total mixed powder, determine the tablet weight and tablet hardness, and use a tablet press to compress the tablets to make tablets; or determine the content and moisture content of the total mixed powder, determine the filling amount, and use a capsule filling machine to fill the capsules to make capsules; (4) Packaging: Add desiccant, tablets or capsules into high-density polyethylene bottles and seal with aluminum foil.

[0071] It is understood that during the preparation process, the order of adding the ingredients, as well as the mixing, tableting or filling, and packaging are carried out according to principles well known in the art.

[0072] The evaluation indexes of prescription screening are the flowability, compressibility and dissolution rate of the total mixed powder. The screening results are shown in Table 4.

[0073] Table 4 Screening of excipients for the tablet formulation of compound II (unit / mg)

[0074] From the results in Table 4, it can be seen that the dissolution of the samples produced by Prescription 1, Prescription 2, and Prescription 4 is unqualified, and the compressibility of Prescription 3 and Prescription 5 is not good; the fluidity of Prescription 1, Prescription 3, and Prescription 6 needs to be improved; and the tablets prepared by selecting microcrystalline cellulose, lactose, and mannitol as fillers have better fluidity and compressibility than other fillers; and when cross-linked sodium carboxymethyl cellulose and pregelatinized starch are selected as disintegrants, they have better dissolution. That is, Prescription 6 is relatively good in both compressibility and dissolution, but it still needs to be optimized if it is expected to be commercially produced.

[0075] Example 3

[0076] To solve the problem in Example 2, the dosage ratio of the filler and the type of lubricant were further adjusted. The tablet preparation process was the same as in Example 2.

[0077] The screening indicators are the flowability, compressibility, dissolution rate and dissolution curve of the total mixed powder. The screening results are shown in Table 5. The dissolution curve comparison of the tablets produced by prescription 7 to prescription 10 in aqueous medium is shown in Table 5. Figure 1 shown.

[0078] Table 5 Screening of filler ratios for tablet formulations of compound of formula II (unit / mg)

[0079] From Table 5, Figure 1 The results show that when the filler of prescription 7 contains only microcrystalline cellulose or most of it is microcrystalline cellulose, the fluidity is poor and the dissolution is slow; after the proportion of mannitol in the filler is gradually increased, the fluidity becomes better and the dissolution becomes faster; the combination of prescriptions 9 and 10 can make the tablets of qualified quality, among which when the ratio of microcrystalline cellulose to mannitol is about 2:1 to 1:1, the product's solubility in acid medium and water medium meets the requirements.

[0080] The above-mentioned prescriptions 9 and 10 both meet the requirements, but the price of mannitol is relatively high, the compatibility of raw materials and auxiliary materials is relatively poor, and the risk of affecting stability is relatively high. After comprehensive consideration, the present invention selects prescription 9 for further study.

[0081] Example 4

[0082] When the quality of the above-mentioned formula 9 meets the requirements, a better formula is further sought by adjusting the amount of disintegrant. The preparation process is the same as that of Example 2.

[0083] The screening indicators are the flowability, compressibility, dissolution rate and dissolution curve of the total mixed powder. The screening results are shown in Table 6. The dissolution curve comparison of the tablets produced by Prescription 11, Prescription 9 and Prescription 12 in aqueous medium is shown in Figure 2 shown.

[0084] Table 6 Screening of disintegrant dosage for tablet formulation of compound of formula II (unit / mg)

[0085] From Table 6, Figure 2The test results show that the above prescriptions also have good fluidity and compressibility during the preparation process. The dosage of disintegrant (cross-linked sodium carboxymethyl cellulose) in prescriptions 11, 9, and 12 gradually increases, and the dissolution rate of the product in the aqueous medium gradually accelerates accordingly; the dissolution of prescription 11 in the aqueous medium is slow, which is not desirable; prescription 12 also dissolves faster only in water, but has no obvious advantage over prescription 9 (45min dissolution is >85%); the present invention comprehensively considers product quality, the cost of disintegrants, and the effect of disintegrants on product stability (cross-linked sodium carboxymethyl cellulose has a high water content, which poses a greater risk to product stability), and finally selects prescription 9 for further research.

[0086] Example 5

[0087] According to the influence of different microcrystalline cellulose types on product stability, auxiliary materials were selected. The tablet preparation process was the same as that in Example 2. The samples produced by Prescription 13 and Prescription 14 were placed at room temperature for 25 days to detect the changes of related substances.

[0088] The indicators for screening microcrystalline cellulose models are related substances and total impurities. The results are shown in Table 7.

[0089] Table 7 Comparison of different types of microcrystalline cellulose in the prescription

[0090] From the results in Table 7, we can see that different microcrystalline celluloses have different moisture contents, which leads to different moisture contents in tablets, and directly leads to different growth rates of related substances in the products. Obviously, when microcrystalline cellulose 102 is used, the growth of related substances is faster, and the risk of unqualified stability is higher; when microcrystalline cellulose 112 is used, the product is more stable. Therefore, prescription 13 was selected for subsequent research.

[0091] Example 6

[0092] Different packaging materials and packaging methods have a great influence on the key quality attributes of the product. The present invention screens the packaging materials of the pharmaceutical composition.

[0093] The evaluation indexes for packaging material screening are related substances and total impurities.

[0094] The present invention packages the samples of prescription 13 in aluminum foil bags, HDPE bottles, and HDPE bottles with different amounts of desiccant, seals the bottles with aluminum foil, and places the packaged products under influencing factor conditions (high temperature 60°C, high humidity 90%RH) for 10 days to compare the changes in related substances in the products. The results are shown in Table 8.

[0095] Table 8 Comparison results of related substances (total impurities) of samples under different packaging conditions

[0096] From the results in Table 8, it can be seen that when the pharmaceutical composition of the present invention is packaged in an aluminum foil bag or a separate HDPE bottle, a large amount of impurities will be generated in the influencing factor test, resulting in unqualified products; the main reason is that the material itself contains moisture and the external high temperature of 60°C accelerates the reaction between the compound of formula II and water, thereby generating a large amount of impurities. HDPE bottles have high water-proof and air-tight properties, which can isolate the influence of external moisture, and adding desiccant can isolate the influence of the moisture content of the material itself. Therefore, when a high-density polyethylene bottle (HDPE bottle) is used with 2g of desiccant added and sealed with aluminum foil, the pharmaceutical composition of the present invention is stable even under extreme storage conditions.

[0097] Tablet stability studies

[0098] The stability evaluation indicators are the key quality attributes of tablets, namely dissolution, content, and related substances.

[0099] Table 9 shows the results of the stability study of the tablets of the compound of formula II and the pharmaceutical preparation described in the packaging prescription 18 (the dosage and excipient types are shown in prescription 13). The samples were stored at 92.5% relative humidity and 60°C for 5 and 10 days, and at light (total illumination of not less than 1.2×10 6 Lux·hr, near ultraviolet energy not less than 200w·hr / m 2 ) for 12 days, and for 6 months under accelerated conditions (40°C 75%RH) and long-term conditions (25°C 65%RH), the impurities and content of the samples in the examples did not change significantly. The results prove that the quality of the tablet pharmaceutical composition of the present invention is stable.

[0100] Table 9 Stability data of compound of formula II tablets

[0101] Note: When the relevant substance is less than 0.05% detection limit, it is described as not detected.

[0102] Example 7 Preclinical studies

[0103] Prior to the present invention, patent application CN114437159 A disclosed the compound of formula I and related research, including the inhibitory effect of the compound of formula I on the new coronavirus, the inhibitory effect of the compound of formula I on feline coronavirus (FIPV), and the pharmacokinetic evaluation of the compound of formula I in rats, and the results showed that: The microtiter plate method was used to evaluate the inhibitory effect of the compound of formula I on the new coronavirus. The results showed that the compound of formula I had a significant inhibitory effect on the three variants of the new coronavirus (Alpha, Delta and Omicron), and the inhibitory effect was significantly better than that of remdesivir, GS-441524, EIDD-1931 and monopivir with free dihydroxy groups at the 2 and 3 positions.

[0104] The inhibitory effect of the compound of formula I on feline coronavirus (FIPV) was evaluated by cell cytopathic effect (CPE). The results showed that when the drug concentration was 12.5 μM, the compound of formula I had a significant inhibitory effect on FIPV, with a cytopathic rate of less than 25%. Its inhibitory effect was significantly better than that of remdesivir, monopivir and GS-441524 with free dihydroxy groups at the 2 and 3-positions.

[0105] At the same time, through the pharmacokinetic evaluation test in rats, the dosage was 0.103 μmol / kg. As shown in Table 10, the compound of formula I has a higher oral bioavailability than GS-441524.

[0106] Table 10 Comparison of pharmacokinetic parameters of the compound of formula I and GS-441524 after oral administration

[0107] Note: ig means oral administration; F means AUC 0-∞ Calculated relative oral bioavailability of GS-441524.

[0108] However, the compound of formula I still has some defects, such as extremely poor water solubility, poor solid powder fluidity, easy degradation, etc., which are not conducive to the preparation and storage of the preparation.

[0109] Therefore, the present invention further prepares the compound of formula I into a salt, and the obtained products such as the compound of formula II and the compound of formula III can effectively improve the above defects. At the same time, through the in vivo pharmacokinetic evaluation test in rats, the dosage is 0.103 μmol / kg. As shown in Table 11, the oral bioavailability of the compound of formula II relative to GS-441524 is 338.6%, which is also significantly higher than that of the compound of formula I.

[0110] Table 11 Comparison of pharmacokinetic parameters of formula II compound and GS-441524 after oral administration

[0111] Note: ig means oral administration; F means AUC 0-∞ Calculated relative oral bioavailability of GS-441524.

[0112] Preclinical studies of a pharmaceutical composition containing a compound of formula II include: a pharmacokinetic study in rats, which designs the effects of different doses and different administration methods on the pharmacokinetic parameters of rats, aiming to evaluate the pharmacokinetic parameters of different doses; and also includes a preclinical experiment, which designs the efficacy and safety of the compound of formula II on feline infectious peritonitis to observe, so as to determine the efficacy and safety of the compound of formula II.

[0113] Study 1: Basic contents and results of pharmacokinetic study: This experiment was divided into 4 groups: oral low-dose group, medium-dose group, high-dose group and intravenous group, with 3 animals / sex in each group. The dosages of each group were 30, 100, 300 and 30 mg / kg, respectively, all of which were single doses. As shown in Table 12.

[0114] Table 12 Rat grouping and dosage table

[0115] Dosage method: For animals in groups 1-3, the specific dosage was calculated according to body weight, the tablets were broken and weighed (the dissolution of the tablets of the present invention in an acid medium was not less than 85% in 15 minutes, and breaking them did not affect the dissolution of the active ingredient), and the test sample was orally administered. For animals in group 4, a disposable sterile syringe and an intravenous infusion needle were used to accurately draw the dose of the test sample, and the drug was injected into the tail vein, and the administration was completed within 1 minute.

[0116] Sample collection was performed by collecting approximately 0.2 mL of whole blood from the jugular vein of the animal at each time point.

[0117] Blood samples were collected from animals in groups 1-3 (oral groups) before drug administration and at 5 min, 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h after drug administration.

[0118] Blood samples were collected from animals in Group 4 (intravenous group) before medication and at 2 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after the start of medication.

[0119] After the blood sample is processed by a certain method, the concentration of the compound of formula II and GS-441524 (degradation product of the compound of formula II) in the sample is detected by a verified LC-MS / MS method.

[0120] The pharmacokinetic data analysis software WinNonlin (8.0.0.3176) was used to analyze the whole blood supernatant concentration data. The non-compartmental model (NCA) method was used to calculate T 1 / 2 , C max , T max and AUC, etc.

[0121] Results During the experiment, no abnormal behavior was observed in any of the animals.

[0122] The drug content in the whole blood supernatant was mainly GS-441524, and the blood concentration of the compound of formula II was low, so the pharmacokinetic parameters were not calculated.

[0123] Table 13 Pharmacokinetic parameters of GS-441524 in whole blood supernatant of male mice after administration of the compound of formula II

[0124] Note: iv means intravenous injection; ig means oral administration; F means AUC 0-∞ Calculation of absolute oral bioavailability.

[0125] Table 14 Pharmacokinetic parameters of GS-441524 in whole blood supernatant of female mice after administration of the compound of formula II

[0126] Note: iv means intravenous injection; ig means oral administration; F means AUC 0-∞ Calculation of absolute oral bioavailability.

[0127] Based on AUC after single intravenous and oral administration 0-∞ It was calculated that the absolute bioavailability (F%) of GS-441524 in male and female rats after a single oral administration of the compound of formula II at 30 mg / kg was 86.52% and 97.43%, respectively.

[0128] After a single intravenous injection and oral administration of Formula II to SD rats, the exposure of GS441524 in rats of different sexes was basically the same. After a single intravenous injection, GS-441524 was cleared from the rats at a high rate. After a single oral administration of 30, 100, and 300 mg / kg of Formula II, the C concentration of GS441524 in the whole blood supernatant of male and female animals was significantly higher than that of female animals. max and AUC last All increased with increasing dose.

[0129] The above examples show that the oral solid preparations containing cyclic carbonate nucleoside analogs of the present invention have high-quality product quality, long-term stability, good pharmacokinetic properties, excellent safety and effectiveness, and can be used to treat diseases caused by viral infections, including pneumonia caused by the new coronavirus and feline infectious peritonitis.

[0130] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A pharmaceutical composition comprising a cyclic carbonate nucleoside analog, characterized in that: It comprises a pharmaceutically acceptable salt of a compound of formula I and excipients, Formula I The auxiliary materials include fillers, disintegrants and lubricants, and the fillers are selected from one or more of lactose, microcrystalline cellulose, starch hydrolyzed oligosaccharides, sorbitol, mannitol and silicified microcrystalline cellulose.

2. The pharmaceutical composition comprising a cyclic carbonate nucleoside analog according to claim 1, characterized in that: The pharmaceutically acceptable salt of the compound of formula I is the hydrobromide of the compound of formula II and / or the hydrochloride of the compound of formula III; Formula II Formula III.

3. The pharmaceutical composition comprising a cyclic carbonate nucleoside analog according to claim 1 or 2, characterized in that: The disintegrant is selected from one or more of modified starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose or cross-linked polyvinylpyrrolidone; Preferably, the disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, and modified starch.

4. The pharmaceutical composition comprising a cyclic carbonate nucleoside analog according to claim 1 or 2, characterized in that: The lubricant is selected from one or more of talc, silicon dioxide, calcium stearate, magnesium stearate, sodium stearyl fumarate or stearic acid; Preferably, the lubricant is selected from one or more of talc, silicon dioxide, magnesium stearate and sodium stearyl fumarate; More preferably, the lubricant is selected from silicon dioxide and / or magnesium stearate.

5. The pharmaceutical composition comprising a cyclic carbonate nucleoside analog according to claim 1 or 2, characterized in that: In terms of weight percentage, the pharmaceutical composition comprises: 5-40% of a pharmaceutically acceptable salt of a compound of formula I, 40-85% of a filler, 2-10% of a disintegrant, and 0.5-8% of a lubricant; Preferably, the pharmaceutical composition comprises, by weight percentage: 10-30% of a pharmaceutically acceptable salt of a compound of formula I, 55-80% of a filler, 3-8% of a disintegrant, and 1-8% of a lubricant; More preferably, the pharmaceutical composition comprises, by weight percentage: 10-15% of a pharmaceutically acceptable salt of the compound of formula I, 70-80% of a filler, 4-8% of a disintegrant and 2-8% of a lubricant.

6. The pharmaceutical composition comprising a cyclic carbonate nucleoside analog according to claim 5, characterized in that: The filler is microcrystalline cellulose and mannitol, the disintegrant is cross-linked carboxymethyl cellulose sodium, and the lubricant is silicon dioxide and magnesium stearate.

7. A pharmaceutical preparation, characterized in that A pharmaceutical composition comprising a cyclic carbonate nucleoside analog as described in any one of claims 1 to 6; Preferably, the pharmaceutical preparation is an oral solid preparation, more preferably a tablet.

8. The method for preparing the pharmaceutical preparation according to claim 7, characterized in that: include: The pharmaceutically acceptable salt of the compound of formula I, filler, disintegrant and lubricant in the prescribed amount are mixed evenly, compressed into tablets by a tablet press or filled into capsules by a capsule filling machine, packaged with a desiccant, and sealed for storage.

9. Use of the pharmaceutical composition comprising a cyclic carbonate nucleoside analogue according to any one of claims 1 to 6 or the pharmaceutical preparation according to claim 7 in the preparation of a medicament for treating and / or preventing diseases caused by viral infection.

10. The use according to claim 9, characterized in that: The viruses include coronavirus, influenza virus, respiratory syncytial virus, Flaviviridae virus, Filoviridae virus, feline coronavirus and feline calicivirus; Preferably, the virus is the new coronavirus SARS-CoV-2, feline infectious peritonitis virus FIPV, respiratory syncytial virus RSV, porcine epidemic diarrhea virus PEDV and / or feline calicivirus FCV.